Laboratory parameters of cardiac and kidney dysfunction in cardio-renal syndromes

Area of Science:

• Cardiology
• Nephrology
• Biomarker Discovery

Background:

• Cardio-Renal Syndromes (CRS) represent complex interactions between cardiac and renal dysfunction.
• Accurate diagnosis and prognostication in CRS patients with co-existing heart failure (HF) and chronic kidney disease (CKD) remain challenging.
• Existing biomarkers may not fully capture the intricate pathophysiology of CRS.

Purpose of the Study:

• To review the role of novel biomarkers in the diagnosis, prognostication, and risk stratification of Cardio-Renal Syndromes.
• To highlight the potential of emerging renal biomarkers for improved evaluation of CRS patients.
• To discuss the utility of natriuretic peptides (NPs) as cardiac biomarkers in HF patients with or without CKD.

Main Methods:

• Literature review of studies investigating biomarkers in Cardio-Renal Syndromes.
• Analysis of research focusing on novel renal biomarkers and established cardiac biomarkers like NPs.
• Examination of biomarker utility across various clinical settings including cardiac surgery, acute coronary syndrome, and HF.

Main Results:

• Novel biomarkers show promise for enhanced evaluation and prognosis in CRS.
• Natriuretic peptides are validated cardiac biomarkers for risk stratification in HF patients, but optimal cutoffs for CKD stages require further definition.
• Current research predominantly focuses on specific clinical scenarios like cardiac surgery and ACS.

Conclusions:

• A multi-biomarker panel approach is likely necessary for optimal evaluation, risk stratification, and management of CRS patients.
• Further research is needed to establish definitive cutoff values for existing biomarkers across all stages of CKD.
• Developing comprehensive biomarker strategies is essential for timely treatment initiation and follow-up in CRS.